- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00423371
Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC
May 18, 2011 updated by: Ferring Pharmaceuticals
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Osteoarthritis (OA) of the First Carpometacarpal (CMC) Joint
This multicenter, double-blind, randomized, parallel-group, active-controlled trial will be performed in approximately 80 subjects with chronic idiopathic osteoarthritis (OA) of the first carpo-metacarpal joint (CMC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
79
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
St. Petersburg, Florida, United States, 33703
- All Florida Orthopedic Association
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men or women ≥40 years of age
- Pain due to primary OA of the first CMC joint present for at least half the days of the previous month AND a mean combined pain score ≥ 30 mm out of 100 mm of the 5 pain questions on the AUSCAN Index Pain Subscale (See Appendix 1)
- A series of X-rays confirming OA of the first CMC joint of the target thumb obtained at screening with a stage of 2, 3, or 4 according to Grading Scale in Appendix 3.
Ability and willingness to use only acetaminophen as the analgesic (rescue) study medication
- The acetaminophen dose must not exceed 4 grams/day (4000 mg)
- If subject has known chronic liver disease, the maximum dose of acetaminophen must not exceed 2 grams/day (2000 mg)
- The subject must be willing and able to discontinue acetaminophen at least 24 hours prior to all study-specific visits
- The study specific acetaminophen provided will only be used for thumb/joint pain.
- Willingness and ability to complete efficacy and safety questionnaires and ability to read and understand study instructions
- Signed study-specific Subject Informed Consent Form
Exclusion Criteria:
- Any major injury to the target thumb within the 6 months prior to the Screening Visit
- Anyone having Carpal Tunnel Syndrome (CTS), DeQuervain's tenosynovitis, trigger finger, or a ganglion cyst of the target hand ONLY IF there is evidence of extreme atrophy AND two-point average discrimination is greater than 10-mm, OR if the pain from these conditions renders the subject unable to objectively assess OA pain in the target hand
- Any surgery to the target joint within the 12 months prior to the Screening Visit
- Regular use of assistive devices such as a cane or crutch or a CTS brace
- Concomitant rheumatic disease (rheumatoid arthritis, lupus arthropathy, psoriatic arthritis)
- History of chondrocalcinosis in the target joint
- Gout exacerbation in any joint in the past 6 months
- X-ray findings of acute fractures, severe loss of bone density, and/or severe bone or joint deformity in the target joint
- Significant target joint infection or skin disorder/infection within the 3 months prior to study enrollment
- Known hypersensitivity to acetaminophen, EUFLEXXA™, or Phosphate Buffered Saline solution
- Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period
- Recurrent medical history of severe allergic or immune-mediated reactions or other immune disorders
- Current treatment or treatment within the previous 2 years prior to the Screening Visit for any malignancy unless specific written permission is provided by the Sponsor (excluding basal cell or squamous cell carcinoma of the skin)
- Active liver disease based on liver profile of AST, ALT, and conjugated bilirubin >2 times the upper limit of normal
- Renal insufficiency based on serum creatinine >2.0 mg/dL
- Any clinically significant laboratory value based on clinical history that the Investigator feels may affect the study evaluation
- Any intercurrent chronic disease or condition that may interfere with the completion of the 6-month follow-up of the study, such as liver disease, severe coronary disease, drug abuse, disordered mental state, or other clinically significant condition
- Current alcoholism, and/or any known current addiction to pain medications
- Any clinically significant finding that would place the subject at health risk, impact the study, or affect the completion of the study
- Any psychiatric illness that would prevent comprehension of the details and nature of the study
- Participation in any experimental device study within 6 months prior to the Screening Visit, or an experimental drug study within 1 month prior to the Screening Visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo is supplied in a disposable prefilled glass syringe.
Each single-dose syringe will contain 2 mL of phosphate buffered saline.
Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
|
Experimental: EUFLEXXA™
|
EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate.
Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in pain scores as reported by the patient on the AUSCAN Index pain subscale
Time Frame: weeks 0 and 26
|
weeks 0 and 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in stiffness and function scores as reported by the patient on the AUSCAN Index stillness and function subscale
Time Frame: weeks 0 and 26
|
weeks 0 and 26
|
Change in Patient Global Assessment of Symptoms measured by 100mm visual analog scale (VAS)
Time Frame: Weeks 0 and 26
|
Weeks 0 and 26
|
Number of tablets of rescue medication used between visits
Time Frame: Weeks 0 and 26
|
Weeks 0 and 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
September 1, 2007
Study Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
January 17, 2007
First Submitted That Met QC Criteria
January 17, 2007
First Posted (Estimate)
January 18, 2007
Study Record Updates
Last Update Posted (Estimate)
May 19, 2011
Last Update Submitted That Met QC Criteria
May 18, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on sodium hyaluronate
-
Democritus University of ThraceGeorge Papanicolaou Hospital; Naval Hospital, Athens; Athinaiki General ClinicCompleted
-
DiscGenics, Inc.CTI Clinical Trial and Consulting ServicesCompletedDegenerative Disc DiseaseUnited States
-
Peking University People's HospitalUnknown
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityUnknownDry Eye | Cataract SenileChina
-
Ferring PharmaceuticalsCompletedInvestigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the KneeOsteoarthritis of the KneeUnited States
-
Laboratorios Sophia S.A de C.V.Completed
-
Laboratorios Sophia S.A de C.V.Completed
-
Hasanuddin UniversityCompleted
-
Laboratorios Sophia S.A de C.V.Active, not recruitingDry Eye SyndromesMexico